The Pharmaceutical Price Regulation Scheme is only into the second year of implementation and already companies are facing rising payments to the Department of Health and may not be reconsidering their options. According to PharmaPhorum.com, “for 2016 through to 2018 it was less clear-cut, because the allowable growth rates were set at 1.8 per cent, 1.8 per cent and 1.9 per cent for the last three years of the scheme.” Take a look at this article to see how companies will be affected by this change: https://pharmaphorum.com/views-and-analysis/stay-or-go-the-uk-s-pprs-and-the-statutory-scheme-for-pricing-branded-medicines/
